Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer

Cancer Research

Volumn 76, Issue 8, 2016, Pages 2301-2313

  Herrera Abreu, Maria Teresa ^a   Palafox, Marta ^b   Asghar, Uzma ^a   Rivas, Martín A ^c   Cutts, Rosalind J ^a   Garcia Murillas, Isaac ^a   Pearson, Alex ^a   Guzman, Marta ^b   Rodriguez, Olga ^b   Grueso, Judit ^b   Bellet, Meritxell ^d   Cortés, Javier ^d   Elliott, Richard ^a   Pancholi, Sunil ^a   Baselga, José ^e   Dowsett, Mitch ^a,f   Martin, Lesley Ann ^a   Turner, Nicholas C ^a,f   Serra, Violeta ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALPELISIB; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYCLIN E1; CYCLIN E2; ESTROGEN RECEPTOR; EVEROLIMUS; FLAVOPIRIDOL; FULVESTRANT; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; RIBOCICLIB; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADAPTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; BREAST CANCER; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER REGRESSION; CELL SURVIVAL; CONTROLLED STUDY; CYTOSTASIS; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; EARLY ADAPTATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE LOSS; GENE SILENCING; IN VITRO STUDY; INTRACELLULAR SIGNALING; MCF 7 CELL LINE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RB1 GENE; S PHASE CELL CYCLE CHECKPOINT; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DRUG RESISTANCE, NEOPLASM; FEMALE; HETEROGRAFTS; HUMANS; MICE; PIPERAZINES; PYRIDINES; RECEPTORS, ESTROGEN;

EID: 84970952279     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0728     Document Type: Article

References (37)

1. Yeo B, Turner NC, Jones A. An update on themedical management of breast cancer. BMJ 2014;348:g3608.
2. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009;15:3654-62.
3. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
5. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21.
6. Kato J, Matsushime H, Hiebert SW, EwenME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993;7: 331-42.
7. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008;8:671-82.
8. Shapiro G, Rosen LS, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, et al. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J Clin Oncol 31, 2013 (suppl; abstr 2500).
9. Infante JR, Shapiro G, Witteveen P, Gerecitano JF, Ribrag V, Chugh R, et al. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncol 32:5s, 2014(suppl; abstr 2528).
10. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER/HER2-advanced breast cancer (PALOMA-1; TRIO-18) [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR. Abstract nr CT101.
11. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 2015;16:25-35.
12. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines invitro. Breast Cancer Res 2009;11:R77.
13. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130-46.
14. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, et al. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011; 1:338-51.
15. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014;26:136-49.
16. Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget 2014;5:6512-25.
17. Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A, et al. Parallel RNA interference screens identify EGFRactivation as an escape mechanismin FGFR3-mutant cancer. Cancer Discov 2013;3:1058-71.
18. Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015;7:302-133.
19. Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 2013;19:3276-84.
20. Caldon CE, Sergio CM, Sutherland RL, Musgrove EA. Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells. Cell Cycle 2013;12:596-605.
21. Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012;104:476-87.
22. Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, et al. Highthroughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 2015;21:1318-25.
23. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015; 373:209-19.
24. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 2002;22:7842-52.
25. Foster JS, Wimalasena J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 1996;10:488-98.
26. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 2009;9:153-66.
27. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-72.
28. Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. Elife 2014;3.
29. VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular pathways: Targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res, 2015;21:2905-10.
30. Malumbres M, Sotillo R, Santamaría D, Galan J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004;118:493-504.
31. Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992;71: 505-14.
32. Jahn SC, Law ME, Corsino PE, Rowe TC, Davis BJ, Law BK. Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes. Biochemistry 2013;52:3489-501.
33. Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, et al. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 2012;11:1488-99.
34. Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, Deal AMMonitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 2013;152:340-51.
35. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
36. Bartkova J, Horejsí Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNAdamage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
37. Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, et al. Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget 2015;6:696-714.